24 results about "Mitoxantrone" patented technology

The invention discloses application of mitoxantrone in preparation of an anti-rabies virus drug, reveals that clinical anti-tumor and immunosuppression drug mitoxantrone has remarkable anti-rabies virus activity for the first time, and opens up a new application field for mitoxantrone. The rigorous in-vitro and in-vivo tests prove that the mitoxantrone can inhibit virus replication in a dose-dependent manner, reduce virus gene and protein expression and remarkably improve the survival rate of infected mice in an animal model. The invention provides a new clinical application approach for mitoxantrone, provides a powerful candidate drug and a brand-new technical scheme for anti-rabies virus drugs, and has important practical significance and clinical application prospects for coping with rabies which is a major public health threat.

The invention discloses a mesoporous polydopamine (MPDA) nanoparticle which is loaded with a CeO2 nano enzyme and mitoxantrone mesylate (MitoQ) and is released by an intestinal tract, a preparation method of the mesoporous polydopamine (MPDA) nanoparticle, and an application of the mesoporous polydopamine (MPDA) nanoparticle, the preparation method of the mesoporous polydopamine (MPDA) nanoparticle, the preparation method of the mesoporous polydopamine (MPDA) nanoparticle and the preparation method of the mesoporous polydopamine (MPDA) nanoparticle, the preparation method of the mesoporous polydopamine (MPDA) nanoparticle, and the preparation method of the mesoporous polydopamine (MPDA) nanoparticle. The mesoporous polydopamine nanoparticle loaded with the CeO2 nano enzyme and the mitoxantrone mesylate and released by the intestinal tract comprises mesoporous polydopamine loaded with the CeO2 nano enzyme and MitoQ, and an enteric coating of chitosan and sodium alginate. The preparation method comprises the following steps: synthesizing mesoporous polydopamine by adopting a triblock copolymer as a template, then loading a small molecular drug MitoQ into MPDA through ultrasonic waves, and loading CeO2 nano-enzyme on the surface of MPDA through metal coordination to form MPDA (at) CeO2-MitoQ. And finally, coating chitosan and sodium alginate on the surfaces of the nanoparticles through electrostatic adsorption to obtain the final MPDA (at) CeO2-MitoQ (at) SA / CS. The drug-loaded nano-particles prepared by the preparation method disclosed by the invention have a good treatment effect on ulcerative colitis.

The application discloses a kind of endoplasmic reticulum of tumor cell can be targeted N -(2-hydroxypropyl) methacrylamide (HPMA) polymer-drug conjugate. The chemotherapeutic drug carried by the HPMA polymer is at least one of doxorubicin, epirubicin, pirarubicin, cisplatin, oxaliplatin, camptothecin, paclitaxel, gemcitabine, methotrexate, vinblastine, mitoxantrone, irinotecan, and the linker for connecting the drug and the HPMA polymer is at least one of hydrazone bond, amide bond, ester bond, disulfide bond, and ketosulfenyl bond. The HPMA polymer-drug conjugate targets the drug to the endoplasmic reticulum through receptor-ligand interaction, can cause severe endoplasmic reticulum stress, thereby transporting a large amount of calnexin to the tumor cell membrane surface, greatly improving the immunogenicity of tumor cells, and promoting tumor immunotherapy.

The invention belongs to the technical field of biological medicine, and discloses application of mitoxantrone liposome (LipoMIT) in preparation of a medicine for inhibiting ovarian cancer stem cells and / or improving ovarian cancer relapse and / or drug resistance. It is found for the first time that LipoMIT has a good inhibiting effect on the ovarian cancer stem cells; the medicine can be used for improving the problems of relapse and drug resistance of ovarian cancer, not only can fill the blank of the problems of drug resistance and relapse in ovarian cancer treatment, but also can fill the technical blank of LipoMIT in the field of ovarian cancer treatment in the prior art. Lipo-MIT plays a role through targeting tumor stem cells, the risk of ovarian cancer recurrence and drug resistance is reduced fundamentally, the bottleneck that only tumor cells are killed but tumor stem cells cannot be eradicated in traditional treatment is broken through, and the clinical problems of high recurrence and high drug resistance of ovarian cancer in the prior art are solved.

The application belongs to the field of new adjuvants and new dosage forms of pharmaceutical preparations, and particularly relates to a type I and type II immunogenic cell death inducer ion pairing engineered nanoassemblies as well as construction and application thereof. The nanoassemblies are composed of type I ICD inducers, type II ICD inducers, hydrophobic auxiliary counterions and amphiphilic lipid ion pairing. The type I ICD inducer is selected from mitoxantrone, doxorubicin, oxaliplatin or cyclophosphamide; the type II ICD inducer is selected from hypericin; and the hydrophobic auxiliary counterion is selected from cholesteryl sodium sulfate, cholic acid, deoxycholic acid, chenodeoxycholic acid, lithocholic acid, glycolcholic acid, taurocholic acid, glycochenodeoxycholic acid, taurochenodeoxycholic acid, deoxycholic acid lysine derivative, oleanolic acid and ursolic acid. The type I and type II ICD inducers are combined in the application, and have a synergistic tumor treatment effect.

The invention discloses a pharmaceutical composition containing a polysialic acid-melittin polyion compound and sialic acid modified anthracycline anti-tumor drug liposome and application of the pharmaceutical composition. The invention belongs to the technical field of biological medicine, and particularly relates to a targeted delivery pharmaceutical composition for treating cold tumors through immunotherapy, and the pharmaceutical composition comprises a polysialic acid-melittin polyion compound and sialic acid modified anthracycline antitumor drug liposome. The anthracycline antitumor drug is selected from one or more of the following components: doxorubicin, epirubicin, pirarubicin, idarubicin, daunorubicin or mitoxantrone. The pharmaceutical composition shows a remarkable synergistic effect in tumor inhibition index, can stimulate congenital immunity and adaptive immunity, induce multiple release of tumor-associated antigens and specific antigens, trigger tumor immune circulation and recover immune control of a body on tumors, and also can enable the body to generate immune memory, so that the tumor inhibition effect is improved. And a new combined treatment strategy is provided for cold tumor treatment.

This invention discloses a non-cationic polymer siRNA and chemical drug co-delivery system, comprising a non-cationic polymer and a complex of siRNA and drug loaded on the polymer; the complex is composed of a target siRNA and a corresponding drug; the non-cationic polymer contains several branches with aromatic rings, the aromatic rings being selected from one or more of 5- to 15-membered aromatic rings or 5- to 15-membered heteroaromatic rings; the drug is selected from one or more of gemcitabine, mitoxantrone, topotecan, beloteccan, irinotecan, doxorubicin, camptothecin, and derivatives of any of the above drugs. This invention enables the synergistic delivery of siRNA and chemical drugs, effectively overcoming the cytotoxicity problems caused by cationic delivery systems, and demonstrates promising application prospects in the field of modern drug delivery.

This invention discloses a supramolecular carrier-free self-delivery system, its preparation method, and its application in tumor treatment, belonging to the field of biomedical technology. The supramolecular carrier-free self-delivery system is prepared by non-covalent self-assembly of mitoxantrone, dihydroporphyrin (Ce6), and ultrasmall iron oxide nanoparticles in an aqueous phase. This invention utilizes the co-assembly of mitoxantrone (MTX), dihydroporphyrin (Ce6), and ultrasmall iron oxide nanoparticles (IONP) to form a supramolecular carrier-free self-delivery system CMIOs. This system is simple to prepare, stable in performance, and highly biosafety. It can synergistically inhibit cancer through multiple mechanisms, achieving highly efficient inhibition of breast cancer, providing a new strategy for tumor treatment, and has broad application prospects in solving clinical problems.

The invention discloses an Au-coated Ag / C-CNF / PEGDA hydrogel SERS (Surface Enhanced Raman Scattering) sensor as well as a preparation method and application thereof, and belongs to the technical field of analysis and detection. Gold and silver nanoparticles with a core-shell structure, polyethylene glycol diacrylate and carboxylated cellulose react to form an Au-coated Ag / C-CNF / PEGDA hydrogel prepolymer solution, and the hydrogel prepolymer solution is subjected to ultraviolet crosslinking under the action of a photoinitiator to form the porous three-dimensional network structure Au-coated Ag / C-CNF / PEGDA hydrogel SERS sensor with a synergistic effect. The hydrogel sensor provided by the invention not only can accurately detect 10 <-9 > M-10 <-5 > M Raman signal molecule rhodamine 6G (R6G), but also has good sensitivity and excellent uniformity, the RSD is as low as 4.92%, and the detection limits on anthracycline antitumor drugs doxorubicin (DOX) and mitoxantrone (MTO) respectively reach 3.4 * 10 <-8 > M and 3.6 * 10 <-9 > M.

The present application relates to a kind of isoquinoline alkaloid derivatives for reversing tumor multidrug resistance by inhibiting autophagy and preparation method and application.The derivative can efficiently reverse the multidrug resistance of various solid tumor cells such as gastric cancer, lung cancer and esophageal cancer, the derivative can inhibit the autophagy flow of tumor cells, it is combined with vincristine, mitoxantrone, colchicine, docetaxel and various chemotherapeutic drugs, can efficiently reverse tumor multidrug resistance in vivo and in vitro, this kind of derivative has excellent oral bioavailability and lower toxic side effects, provides a kind of alternative strategy for autophagy inhibitor as antitumor chemosensitizer, can be used as lead compound for the research and development of new drug-resistant tumor reversing agent.

The invention relates to the technical field of functional dyes, and particularly discloses a high-weather-resistance blue dye and a preparation method and application thereof.The preparation method of the high-weather-resistance blue dye comprises the following steps that S1, mitoxantrone, 3-bromine-1-amidonaphthalene, a catalyst and an organic solvent are mixed and then heated and stirred for a reaction, a solid is obtained through filtering, and the solid is dried; washing with water and ethanol, and drying to obtain a dye intermediate A; and S2, mixing the dye intermediate A with 2-amino-4 '-methoxybenzophenone, a catalyst and an organic solvent, heating, stirring and reacting, extracting, carrying out rotary evaporation to obtain a solid, recrystallizing, and drying to obtain the high-weather-resistance blue dye. The benzophenone structure is introduced into the anthraquinone dye, so that the light resistance and the heat resistance of the anthraquinone dye are synchronously improved fundamentally.

The invention relates to a nano drug delivery system co-carrying a pyruvate dehydrogenase kinase inhibitor and mitoxantrone as well as a preparation method and application of the nano drug delivery system, and belongs to the technical field of pharmaceutical preparations. A pyruvate dehydrogenase kinase inhibitor and mitoxantrone are jointly loaded on the metal organic framework ZIF-90 nano material in sequence through a simple and rapid method, and the nano drug delivery system is prepared. The nano drug delivery system can target tumor cell mitochondria, responds to release drugs in an acidic tumor microenvironment, realizes multi-mode synergistic treatment of chemotherapy-glycometabolism treatment through the synergistic effect of metabolism reprogramming and redox imbalance, and significantly enhances the anti-tumor effect.

The application of mitoxantrone in inducing IRF4 protein degradation through autophagy-lysosome pathway belongs to the field of biological medicine. Mitoxantrone can specifically bind to IRF4 protein and significantly reduce the level of IRF4 protein. Mitoxantrone mainly binds to the DNA binding domain of IRF4, shortens the half-life of IRF4 protein, and promotes its degradation through the autophagy-lysosome pathway rather than the proteasome pathway. Mitoxantrone can interact with IRF4 protein and autophagy receptor p62 at the same time, promote the formation of IRF4 and p62 complex, enhance the ubiquitination modification of IRF4 and recruit it to the autophagy degradation pathway, thereby playing the role of molecular glue. Mitoxantrone treatment can inhibit the transcriptional activation function mediated by IRF4, down-regulate the expression of its downstream target genes, inhibit the proliferation of multiple myeloma cells and tumor growth, and provide a new technical approach for the development of anti-tumor drugs targeting transcription factors.

The application is a metabolic regulation medium and a method for inhibiting diploidization of haploid embryonic stem cells by using the same, which comprises a basic medium and a metabolic regulation functional component, and the metabolic regulation functional component comprises Mitoquinone mesylate, Emricasan, Forsfructose, 2-Deoxy-D-glucose, UK5099 and VLX600. A new culture system of mouse haploid embryonic stem cells is established, and the haploid maintenance effect, cell pluripotency, differentiation ability and genomic stability of the system are systematically verified. The application can significantly improve the haploid maintenance ability of haploid embryonic stem cells and reduce the culture cost, and provides a simple and economical culture strategy for the popularization and application of haploid embryonic stem cells.

The invention discloses a pharmaceutical composition and a liposome. The pharmaceutical composition comprises emidine with the concentration not lower than 0.01 M and mitoxantrone with the concentration not lower than 0.003 M, and is used for treating breast cancer. The liposomes include at least three lipids (including DPPC, DSPE-PEG (2000) amine, and cholesterol) and comprise the composition.

Disclosed are a use of Mitoxantrone or an isomer, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt thereof, a prodrug thereof, or a derivative thereof in the preparation of a drug for treating or preventing neuroendocrine tumor, and a method for treating or preventing neuroendocrine tumor. Research shows that Mitoxantrone can inhibit the growth of neuroendocrine tumor in a dose-dependent manner, has high drug sensitivity and significant tumor inhibition effect, is a new candidate drug for the clinical treatment of neuroendocrine tumor, and has high clinical value.

The invention discloses a tetrahydroisoquinoline-indole-pyrimidine compound and preparation and application thereof.The tetrahydroisoquinoline-indole-pyrimidine compound has good biological activity, can inhibit the activity of P-gp protein and BCRP protein at the same time, has an excellent MDR reversing effect and enhances the sensitivity of malignant tumor cells to anti-tumor drugs doxorubicin hydrochloride and mitoxantrone, and has a good application prospect. The compound can be used for development and utilization of drugs for treating multidrug resistance of malignant tumor cells caused by P-gp protein and BCRP protein, and is expected to become a potential multidrug resistance protein inhibitor for treating MDR.

(3R, 4S)-3-(4-hydroxy-3,5-dimethoxyphenyl)-4-(4-hydroxyphenyl)-8-methyl-3,4-dihydro-2H- chromen-7-ol (TRX-E-002-1) for use in a method of treatment for a hematological cancer being acute myeloid leukemia or multiple myeloma in a subject in need thereof, the method comprising administering to the subject an effective amount of TRX-E-002-1. The method may further comprise administering to the subject an effective amount of a second compound selected from the group consisting of (i) a BCL-2 inhibitor such as venetoclax, navitoclax or obatoclax, (ii) a deoxycytidine analogue chemotherapeutic such as cytarabine or gemcitabine, (iii) a hypomethylating agent such as azacitidine or decitabine, (iv) an anthracycline chemotherapeutic such as daunorubicin, doxorubicin, epirubicin, idarubicin, valrubicin or mitoxantrone, (v) a proteasome inhibitor such as carfilzomib, bortezomib, and ixazomib, (vi) an immunomodulatory drug such as pomalidomide, lenalidomide, and thalidomide and(vii) a corticosteroid drug such as dexamethasone or prednisone, and (viii) an alkylator such as bendamustine, cyclophosphamide, melphalan, and melflufen. Corresponding combination pharmaceutical compositions.

The invention discloses an N, 4-diphenylpyrimidine-2-amine compound and preparation and application thereof.The N, 4-diphenylpyrimidine-2-amine compound can remarkably reverse tumor MDR, enhance the sensitivity of malignant tumor cells to anti-tumor drugs such as doxorubicin hydrochloride and mitoxantrone and improve the drug-resistant tumor apoptosis rate, has good potential in the aspect of MDR reversing and has important development prospects.

The use of a mitoxantrone preparation in the preparation of a drug for diagnosing and treating breast cancer. Provided is the use of mitoxantrone and / or a pharmaceutically acceptable salt thereof in the preparation of a lymphatic tracer in a disease associated with breast resection. No local or systemic toxic and side effects are seen after local injection of the preparation, suggesting that the preparation has good tolerance, effectiveness and safety, which provides a new treatment idea for thoroughly curing breast cancer in a breast cancer patient.

A mitoxantrone liposome and capecitabine are used in treating nasopharyngeal carcinoma, in particular recurrent and / or metastatic nasopharyngeal carcinoma. Nasopharyngeal carcinoma, in particular recurrent and / or metastatic nasopharyngeal carcinoma, can be treated by administering a therapeutically effective dose of the mitoxantrone liposome and capecitabine to a patient with nasopharyngeal carcinoma.

The application relates to a mitoxantrone-cholesterol prodrug and self-assembled nanoparticles and a preparation method thereof, and belongs to the technical field of medicines, and particularly relates to a redox-sensitive mitoxantrone-cholesterol prodrug and construction of self-assembled nanoparticles containing the prodrug, and application of the self-assembled nanoparticles in the field of drug delivery. A 2,2'-dithiodiglycolic acid bridged mitoxantrone-cholesterol prodrug is synthesized, and a prodrug self-assembled nanoparticle is prepared. The mitoxantrone-cholesterol prodrug self-assembled nanoparticle of the application significantly reduces the systemic toxicity of mitoxantrone on the basis of ensuring the curative effect, and has better tolerance and a higher tolerance dose.

The invention discloses a pharmaceutical composition for treating drug-resistant brain glioma, and belongs to the technical field of biological medicines.The pharmaceutical composition comprises at least one blood-brain barrier opener and at least one drug-resistant brain glioma chemotherapy drug, the blood-brain barrier opener is arginine or hydroxyurea, and the drug-resistant brain glioma chemotherapy drug is a drug-resistant brain glioma chemotherapy drug. The drug-resistant brain glioma chemotherapeutic drug comprises doxorubicin hydrochloride, mitoxantrone or methotrexate. The blood-brain barrier opener and the drug-resistant brain glioma chemotherapeutic drug are combined for treatment of drug-resistant brain glioma, the blood-brain barrier opener arginine or hydroxyurea can obviously increase the accumulation amount of the chemotherapeutic drug in the brain, and the pharmaceutical composition can effectively inhibit the growth of the drug-resistant brain glioma and prolong the lifetime of a model animal. According to the technical scheme, a new solution is provided for overcoming the blood-brain barrier and treating the drug-resistant brain glioma.

This invention relates to a CuO2-metal-organic framework composite nanomaterial, its preparation method, and its application. The CuO2-metal-organic framework composite nanomaterial comprises a carrier, a photothermal agent, and a drug. The carrier comprises core-shell structured nanoparticles and folic acid. The core-shell structured nanoparticles comprise a core and a shell. The core comprises copper peroxide, and the shell comprises a metal-organic framework, including ZIF-67. The core is encapsulated within the shell. The photothermal agent comprises indocyanine green, and the drug comprises mitoxantrone. The photothermal agent and the drug are loaded onto the carrier. The preparation method includes the preparation of the core-shell structured nanoparticles, the preparation of the carrier, and the preparation of the composite nanomaterial. This invention constructs a quadruple synergistic therapeutic system integrating photothermal, chemotherapy, chemokinetics, and immune activation, significantly enhancing the induction of immunogenic cell death effects and successfully extending the therapeutic effect from local tumor killing to systemic anti-tumor immune activation.